Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with guillain-barré syndrome

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Li, Cong ^a   Zhao, Pingwei ^a   Sun, Xiguang ^a   Che, Yuanyuan ^a   Jiang, Yanfang ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 17; INTERLEUKIN 37; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL37 PROTEIN, HUMAN; INTERLEUKIN 1;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FUNCTIONAL STATUS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RATING SCALE; TREATMENT DURATION; BLOOD; CASE CONTROL STUDY; CEREBROSPINAL FLUID; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-1; INTERLEUKIN-17; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84885571613     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/639712     Document Type: Article

References (32)

1. Ho T., Griffin J., Guillain-Barré syndrome. Current Opinion in Neurology 1999 12 4 389 394 10.1097/00019052-199908000-00004 (Pubitemid 30028735)
2. Fish M., Llewelyn G., The Guillain-Barré syndrome. ACNR 2008 8 4, article 11
3. Nadkar M. Y., Bajpai S., Itolikar M., Guillain-Barré syndrome: a common neurological entity with myriad manifestations. JAPI 2013 61 165 166
4. Ang C. W., Jacobs B. C., Laman J. D., The Guillain-Barré syndrome: a true case of molecular mimicry. Trends in Immunology 2004 25 2 61 66 10.1016/j.it.2003.12.004 (Pubitemid 38167486)
5. van Doorn P. A., Ruts L., Jacobs B. C., Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. The Lancet Neurology 2008 7 10 939 950 2-s2.0-51449103646 10.1016/S1474-4422(08)70215-1
6. Zhu W., Mix E., Nennesmo I., Adem A., Zhu J., Anti-cytokine autoantibodies in experimental autoimmune neuritis in Lewis rats. Experimental Neurology 2004 190 2 486 494 2-s2.0-8644255282 10.1016/j.expneurol.2004.08.017 (Pubitemid 39505002)
7. van der Meché F. G. A., van Doorn P. A., Meulstee J., Jennekens F. G. I., Diagnostic and classification criteria for the Guillain-Barré syndrome. European Neurology 2001 45 3 133 139 2-s2.0-0035051829 10.1159/000052111 (Pubitemid 32304690)
8. Nyati K. K., Prasad K. N., Rizwan A., Verma A., Paliwal V. K., TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barré syndrome. Archives of Neurology 2011 68 4 445 452 2-s2.0-79953894884 10.1001/archneurol. 2011.51
9. Lu M. O., Zhu J., The role of cytokines in Guillain-Barré syndrome. Journal of Neurology 2011 258 4 533 548 10.1007/s00415-010-5836-5
10. Yu J. J., Gaffen S. L., Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Frontiers in Bioscience 2008 13 1 170 177 2-s2.0-38449121963 10.2741/2667 (Pubitemid 351594768)
11. Miossec P., IL-17 and Th17 cells in human inflammatory diseases. Microbes and Infection 2009 11 5 625 630 2-s2.0-67349234068 10.1016/j.micinf.2009.04.003
12. Boraschi D., Lucchesi D., Hainzl S., Leitner M., Maier E., Mangelberger D., Oostingh G. J., Pfaller T., Pixner C., Posselt G., Italiani P., Nold M. F., Nold-Petry C. A., Bufler P., Dinarello C. A., IL-37: a new anti-inflammatory cytokine of the IL-1 family. European Cytokine Network 2011 22 3 127 147 2-s2.0-83055163376 10.1684/ecn.2011.0288
13. Kumar S., McDonnell P. C., Lehr R., Tierney L., Tzimas M. N., Griswold D. E., Capper E. A., Tal-Singer R., Wells G. I., Doyle M. L., Young P. R., Identification and initial characterization of four novel members of the interleukin-1 family. The Journal of Biological Chemistry 2000 275 14 10308 10314 2-s2.0-0034616346 10.1074/jbc.275.14.10308 (Pubitemid 30202089)
14. Nold M. F., Nold-Petry C. A., Zepp J. A., Palmer B. E., Bufler P., Dinarello C. A., IL-37 is a fundamental inhibitor of innate immunity. Nature Immunology 2010 11 11 1014 1022 2-s2.0-77958149102 10.1038/ni.1944
15. Akdis M., Burgler S., Crameri R., Eiwegger T., Fujita H., Gomez E., Klunker S., Meyer N., O'Mahony L., Palomares O., Rhyner C., Quaked N., Schaffartzik A., van de Veen W., Zeller S., Zimmermann M., Akdis C. A., Interleukins, from 1 to 37, and interferon- γ: receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology 2011 127 3 701 721 2-s2.0-79952291528 10.1016/j.jaci.2010.11.050
16. Asbury A. K., Cornblath D. R., Assessment of current diagnostic criteria for Guillain-Barré syndrome. Annals of Neurology 1990 27 S21 S24 2-s2.0-0025375133 10.1002/ana.410270707 (Pubitemid 20178648)
17. Hughes R. A. C., Newsom-Davis J. M., Perkin G. D., Pierce J. M., Controlled trial of prednisolone in acute polyneuropathy. The Lancet 1978 2 8093 750 753 2-s2.0-0018119702 (Pubitemid 9034500)
18. Morgan E., Varro R., Sepulveda H., Ember J. A., Apgar J., Wilson J., Lowe L., Chen R., Shivraj L., Agadir A., Campos R., Ernst D., Gaur A., Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clinical Immunology 2004 110 3 252 266 2-s2.0-12144290406 10.1016/j.clim.2003.11.017 (Pubitemid 38402005)
19. Tárnok A., Hambsch J., Chen R., Varro R., Cytometric bead array to measure six cytokines in twenty-five microliters of serum. Clinical Chemistry 2003 49 6 1000 1002 2-s2.0-0037683294 10.1373/49.6.1000 (Pubitemid 36623495)
20. Pithadia A. B., Kakadia N., Guillain-Barré syndrome (GBS). Pharmacological Reports 2010 62 2 220 232 2-s2.0-77953308800
21. Hughes R. A. C., Hadden R. D. M., Gregson N. A., Smith K. J., Pathogenesis of Guillain-Barré syndrome. Journal of Neuroimmunology 1999 100 1-2 74 97 2-s2.0-0033375608 10.1016/S0165-5728(99)00195-2 (Pubitemid 30038241)
22. Zhang H. L., Azimullah S., Zheng X. Y., Wang X., Amir N., Mensah-Brown E. P., Al Shamsi M., Shahin A., Press R., Zhu J., Adem A., IFN- γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response. Journal of Neuroimmunology 2012 246 1-2 18 26 2-s2.0-84860155310 10.1016/j.jneuroim.2012.02.011
23. Li S., Yu M., Li H., Zhang H., Jiang Y., IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome. Mediators of Inflammation 2012 2012 7 260473 10.1155/2012/260473
24. Lambracht-Washington D., Wolfe G. I., Cytokines in Guillain-Barré syndrome: a lesson in time. Archives of Neurology 2011 68 4 427 428 2-s2.0-79953891365 10.1001/archneurol.2011.47
25. Sharma S., Kulk N., Nold M. F., Gräf R., Kim S. H., Reinhardt D., Dinarello C. A., Bufler P., The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. Journal of Immunology 2008 180 8 5477 5482 2-s2.0-45949111754
26. Banchereau J., Pascual V., O'Garra A., From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nature Immunology 2012 13 10 925 931 10.1038/ni.2406
27. Song L., Qiu F., Fan Y., Ding F., Liu H., Shu Q., Liu W., Li X., Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. Journal of Clinical Immunology 2013 33 1 111 117 10.1007/s10875-012-9791-z
28. Tete S., Tripodi D., Rosati M., Conti F., Maccauro G., Saggini A., Cianchetti E., Caraffa A., Antinolfi P., Toniato E., Castellani M. L., Conti P., Theoharides T. C., IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. International Journal of Immunopathology and Pharmacology 2012 25 1 31 38
29. McNamee E. N., Masterson J. C., Jedlicka P., McManus M., Grenz A., Collins C. B., Nold M. F., Nold-Petry C., Bufler P., Dinarello C. A., Rivera-Nieves J., Interleukin 37 expression protects mice from colitis. Proceedings of the National Academy of Sciences of the United States of America 2011 108 40 16711 16716 2-s2.0-80053624991 10.1073/pnas.1111982108
30. Bulau A. M., Fink M., Maucksch C., Kappler R., Mayr D., Wagner K., Bufler P., In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. TheScientificWorldJOURNAL 2011 11 2480 2490 2-s2.0-84855585934 10.1100/2011/968479
31. Sakai N., van Sweringen H. L., Belizaire R. M., Quillin R. C., Schuster R., Blanchard J., Burns J. M., Tevar A. D., Edwards M. J., Lentsch A. B., IL-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. Journal of Gastroenterology and Hepatology 2012 27 10 1609 1616 10.1111/j.1440-1746.2012.07187.x
32. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A., Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Medicine 2007 13 10 1173 1175 2-s2.0-34948909646 10.1038/nm1651 (Pubitemid 47530640)